Zacks Research Analysts Lower Earnings Estimates for Danaher

Danaher Co. (NYSE:DHR) – Investment analysts at Zacks Research decreased their FY2024 earnings per share estimates for Danaher in a report issued on Tuesday, November 12th. Zacks Research analyst R. Department now forecasts that the conglomerate will earn $7.49 per share for the year, down from their previous estimate of $7.56. The consensus estimate for Danaher’s current full-year earnings is $7.51 per share. Zacks Research also issued estimates for Danaher’s Q4 2024 earnings at $2.14 EPS, Q1 2025 earnings at $2.05 EPS, Q2 2025 earnings at $1.91 EPS, Q3 2025 earnings at $1.94 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $8.24 EPS, Q1 2026 earnings at $2.21 EPS, Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $9.28 EPS.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.02 EPS.

DHR has been the subject of several other research reports. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Wells Fargo & Company started coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Royal Bank of Canada reduced their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, TD Cowen lifted their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Price Performance

Shares of DHR stock opened at $241.47 on Thursday. The firm has a market capitalization of $174.41 billion, a price-to-earnings ratio of 46.08, a price-to-earnings-growth ratio of 4.40 and a beta of 0.85. Danaher has a 12-month low of $200.36 and a 12-month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm has a fifty day moving average of $263.88 and a 200-day moving average of $260.77.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s payout ratio is currently 20.61%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently modified their holdings of DHR. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter worth $25,000. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the 2nd quarter valued at $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher during the 3rd quarter worth $40,000. Darwin Wealth Management LLC bought a new position in Danaher during the third quarter valued at about $55,000. Finally, MFA Wealth Advisors LLC purchased a new position in Danaher in the second quarter valued at about $51,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.